Zymeworks Announces $200 Million Share Repurchase Authorization
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Zymeworks (Nasdaq: ZYME) authorized a second 2026 share repurchase program allowing purchases of up to $200.0 million of common stock. The company intends to begin before the end of 2026 and expects to spend approximately $140.0 million through 2028.
Funding will come from its existing balance sheet and expected cash flows: $55 million in upfront fees from the Roche collaboration closing, expected before year-end 2026 pending HSR clearance, and a potential $100 million TRELEGY ELLIPTA milestone payment expected in the first quarter of 2027, subject to the applicable 2026 sales threshold. Zymeworks completed its initial 2026 repurchase program, which authorized up to $125.0 million. Approximately 68.7 million common shares were outstanding as of November 11, 2026.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate point. Forward-looking: it has not happened yet and may not happen.Up to $200.0 million authorized for repurchases through 2028; approximately $140.0 million expected, starting before year-end 2026. 11% of market cap
- Moderate point. Forward-looking: it has not happened yet and may not happen.$55 million in upfront fees expected from Roche collaboration closing before year-end 2026 would help fund repurchases. 3% of market cap
- Moderate point. Forward-looking: it has not happened yet and may not happen.Potential $100 million TRELEGY ELLIPTA milestone payment expected in the first quarter of 2027 would help fund repurchases. 5.4% of market cap
- Minor pointInitial 2026 repurchase program completed, following authorization to repurchase up to $125.0 million.
- Minor point. Forward-looking: it has not happened yet and may not happen.2027 capital allocation plans include pipeline development and selective acquisitions alongside opportunistic repurchases.
Negative
- Minor pointRoche collaboration closing remains pending HSR clearance, a condition for the expected upfront funding.
- Minor point. Forward-looking: it has not happened yet and may not happen.TRELEGY ELLIPTA milestone payment depends on achievement of the applicable 2026 sales threshold.
News Explained
The Zymeworks
Key Figures
- Repurchase authorization
- Up to $200.0 million
- Second 2026 program; repurchases may continue through 2028
- Expected repurchases
- Approximately $140.0 million
- Company currently expects this spending through 2028
- Roche upfront fees
- $55 million
- Expected before the end of 2026; pending HSR clearance
- TRELEGY ELLIPTA milestone
- Potential $100 million
- Expected in the first quarter of 2027, subject to achievement of the applicable 2026 sales threshold
Previous Buybacks Reports
-
Authorized up to $125 million in 2026 repurchases after ending the 2025 program
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
hsr clearance regulatory
rule 10b5-1 regulatory
rule 10b-18 regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Zymeworks intends to commence the Share Repurchase Program with
$140.0 million in share repurchases expected through 2028, with flexibility to adjust the pace of repurchases based on market opportunities, cash flow, and expected contribution to Total Shareholder Return (TSR) - Zymeworks intends to balance capital allocation for 2027 thoughtfully across disciplined R&D pipeline development, selective M&A transactions and opportunistic share repurchases to grow underlying enterprise value while returning capital to shareholders through reducing share count over time
VANCOUVER, British Columbia, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that its Board of Directors has authorized a second 2026 share repurchase program under which the Company may repurchase up to
Zymeworks completed its initial 2026 share repurchase program under which the Company was authorized to repurchase up to
Zymeworks intends to commence the second 2026 Share Repurchase Program before the end of 2026, which authorizes up to
“As we look ahead, our focus remains on allocating capital thoughtfully to support long-term growth and shareholder value,” said Kristin Stafford, CPA, Chief Financial Officer of Zymeworks. “Our priorities include disciplined pipeline development, selective M&A and opportunistic share repurchases, with
The Share Repurchase Program will be funded through the Company’s existing balance sheet, and expected near-term cash flows of
About Zymeworks Inc.
Zymeworks is a global biotechnology company building a diversified portfolio of healthcare assets designed to generate durable cash flows while advancing innovative medicines for difficult-to-treat diseases. The Company’s asset and royalty aggregation strategy combines a growing portfolio of commercial and near-commercial assets, including YUPELRI® (revefenacin), with a differentiated internal research and development engine. Zymeworks’ portfolio also includes Ziihera® (zanidatamab-hrii), a HER2-targeted bispecific antibody discovered and developed by Zymeworks and commercialized through global partnerships with Jazz Pharmaceuticals and BeOne Medicines, and pasritamig, a clinical-stage multispecific antibody developed by Johnson & Johnson using Zymeworks’ proprietary antibody engineering technologies.
Zymeworks is advancing a diverse pipeline of novel biotherapeutics, leveraging its proprietary Azymetric™ platform and expertise in antibody-drug conjugates, multispecific antibodies and other next-generation antibody technologies. These capabilities, together with Zymeworks’ integrated drug development expertise, enable the Company to develop differentiated therapeutics and create value through both internal innovation and strategic partnerships.
For more information about Zymeworks, its portfolio and pipeline, visit www.zymeworks.com and follow @ZymeworksInc on X.
Cautionary Note Regarding Forward-Looking Statements
This press release includes “forward-looking statements” or information within the meaning of the applicable securities legislation, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this press release include, but are not limited to, statements that relate to Zymeworks’ ability to execute the share repurchase program, in whole or in part; HSR clearance and the closing of the agreement with Roche; achievement of the applicable 2026 sales threshold for TRELEGY ELLIPTA®; Zymeworks’ flexibility to invest in its R&D pipeline and pursue strategic opportunities while returning capital to stockholders; expected benefits to stockholders of share repurchases; Zymeworks’ expectations regarding implementation of its long-term strategy to maximize value creation; Zymeworks’ and its partners’ clinical development of product candidates; potential safety profile and therapeutic effects of product candidates; the commercial potential of technology platforms and product candidates; the anticipated benefits of its collaboration agreements; and other information that is not historical information. When used herein, words such as “plan”, “believe”, “expect”, “may”, “continue”, “anticipate”, “potential”, “will”, “on track”, “progress”, “preserve”, “intend”, “could”, and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Zymeworks’ current expectations and various assumptions. Zymeworks believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Zymeworks may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various factors, including, without limitation: any of Zymeworks’ or its partners’ product candidates may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; Zymeworks may not be able to successfully execute the share repurchase program; the anticipated benefits of the share repurchase program may not be realized; Zymeworks may not achieve milestones or receive additional payments or royalties under its collaborations; regulatory agencies may impose additional requirements or delay the initiation of clinical trials; the impact of new or changing laws and regulations; market conditions, including the impact of tariffs; potential negative impacts of FDA regulatory delays and uncertainty around recent policy developments, changes in the leadership of federal agencies such as the FDA, staff layoffs, budget cuts to agency programs and research, and changes in drug pricing controls; the impact of pandemics and other health crises on Zymeworks’ business, research and clinical development plans and timelines and results of operations, including impact on its clinical trial sites, collaborators, and contractors who act for or on Zymeworks’ behalf; zanidatamab may not be successfully commercialized; Zymeworks’ business strategy related to anticipated and potential future milestones and royalty streams and existing and potential new partnerships may not be successfully implemented; Zymeworks’ evolution of its business strategy may not deliver meaningful stockholder returns; Zymeworks may be unsuccessful in actively managing and/or aggregating revenue-generating assets alongside its active R&D operations; ongoing and future clinical trials may not demonstrate safety and efficacy of any of Zymeworks’ or its collaborators’ product candidates; data providing early validation of our antibody drug conjugate platform and next generation pipeline programs may not be replicated in future studies; Zymeworks’ assumptions and estimates regarding its financial condition, future financial performance and estimated cash runway may be incorrect; inability to maintain or enter into new partnerships or strategic collaborations; the inability of Zymeworks to identify and consummate a strategic acquisition; and the factors described under “Risk Factors” in Zymeworks’ quarterly and annual reports filed with the Securities and Exchange Commission (copies of which may be obtained at www.sec.gov and www.sedarplus.ca).
Although Zymeworks believes that such forward-looking statements are reasonable, there can be no assurance they will prove to be correct. Investors should not place undue reliance on forward-looking statements. The above assumptions, risks and uncertainties are not exhaustive. Forward-looking statements are made as of the date hereof and, except as may be required by law, Zymeworks undertakes no obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances, or to reflect the occurrences of unanticipated events.
Contacts:
Investor Inquiries:
Shrinal Inamdar
Vice President, Investor Relations
(604) 678-1388
ir@zymeworks.com
Media Inquiries:
Diana Papove
Vice President, Corporate Communications
(604) 678-1388
media@zymeworks.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.